Onivyde pegylated liposomal 4.3 mg/ml Dispersion for infusion 10ml Vial
Product Overview
Discover Onivyde pegylated liposomal 4.3 mg/ml Dispersion for infusion 10ml Vial, a specialized prescription medication for the treatment of metastatic pancreatic cancer.
Trusted by healthcare professionals and aligning with the high standards of pharmaceutical products found on platforms like Nahdi Online, , and , Onivyde offers advanced therapeutic support.
Developed by Ipsen, this advanced formulation delivers irinotecan, an antineoplastic agent, encapsulated within pegylated liposomes to improve its pharmacokinetic profile and targeting capabilities.
It is typically used in combination with fluorouracil and leucovorin for patients whose disease has progressed following gemcitabine-based therapy.
Benefits of Use
- Targets metastatic pancreatic cancer cells.
- Utilizes pegylated liposomal technology for enhanced drug delivery and sustained release of irinotecan.
- Approved for use in patients who have previously undergone gemcitabine-based chemotherapy.
- Administered under strict medical supervision for optimal patient outcomes.
How to Use
- Onivyde is administered by a qualified healthcare professional.
- It is given as an intravenous infusion.
- The specific dosage, infusion rate, and treatment schedule will be determined by your physician based on your medical condition and response to therapy.
- Always follow the instructions and guidance provided by your healthcare team.
Caution & Warnings
- Severe Myelosuppression: May cause a significant decrease in white blood cells, red blood cells, and platelets. Close monitoring of blood counts is essential.
- Severe Diarrhea: Both early and late-onset diarrhea can occur and may be life-threatening. Prompt management is crucial.
- Hypersensitivity Reactions: Allergic reactions, including anaphylaxis, have been reported.
- Embryo-Fetal Toxicity: Can cause harm to a fetus. Effective contraception is advised for patients of reproductive potential during treatment and for a specified period after.
- Extravasation Risk: Exercise caution during administration to avoid extravasation, which can lead to tissue damage.
- This medication must only be administered by a physician or under their direct supervision, experienced in the use of anticancer agents.
Ingredients
Active Ingredient: Irinotecan hydrochloride trihydrate (encapsulated in pegylated liposomes).
Other Ingredients: Hydrogenated soy phosphatidylcholine, cholesterol, methoxy-polyethylene glycol-distearoylglycerol (MPEG-2000-DSPE), sucrose, succinic acid, sodium chloride, water for injection.
Product Details
- Brand: Onivyde
- Manufacturer: Ipsen
- Form: Dispersion for Infusion
- Strength: 4.3 mg/ml
- Volume: 10 ml Vial
- Administration Route: Intravenous
- Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze.
- Legal Status: Prescription Only Medicine (POM)
| Gtin | 2208245808 |
|---|---|
| Recommended Sale Price | 4171.55 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | IRINOTECAN |
| SFDA Reg. No | 2208245808 |
| IBC | 2208245808 |
| Drug Type | prescription |
| Scientific Name | Irinotecan hydrochloride trihydrate |
| Strength | 4.3 |
| Strength Unit | mg/ml |
| Form | Dispersion for Infusion |
| Admin Route | Intravenous |
| Size | 10 |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | 10 ml |
| shelfLife | 24 months |
| Storage conditions | Store refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. |
| Refrigerator Storage | Yes |
